IsoRay Stock Quote Today

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:3em;padding-top: 38px;;'>ISR</div>
IsoRay is selling at 0.7053 as of the 5th of June 2020; that is 0.06 percent increase since the beginning of the trading day. The stock's lowest day price was 0.7. IsoRay has a very small chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 30 days. Equity ratings for IsoRay Inc are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 7th of March 2020 and ending today, the 5th of June 2020. Click here to learn more.
Analyze Filter   Fiscal Quarter End: 30th of June 2020

3 100 

IsoRay Profile

Next fiscal quarter end is expected on 30th of June 2020. IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington. IsoRay operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 43 people. more on IsoRay
IsoRay Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
IsoRay Inc SEC Filings
IsoRay SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameIsoRay Inc
CEOLori WoodsView All
Thematic Classification
Currently Active Investing Idea
  Medical Equipment
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering IsoRay Inc. The IsoRay consensus assessment is calculated by taking the average estimates from all of the analysts covering IsoRay
Strong Buy2 Opinions
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of IsoRay Inc financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares67.3 M77.1 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted65 M77.1 M
Fairly Down
Slightly volatile
Net Cash Flow from Operations(5.5 M)(4.5 M)
Fairly Down
Slightly volatile
Total Assets18.1 M10.8 M
Way Up
Very volatile
Total Liabilities2.1 MM
Notably Up
Current Assets13.6 M8.4 M
Way Up
Current Liabilities1.1 M1.3 M
Fairly Down
Slightly volatile
Total Debt462.2 K162 K
Way Up
Return on Average Assets(0.0044)(0.4104)
Way Down
Gross Margin0.51740.4796
Significantly Up
Slightly volatile
Asset Turnover0.50150.5814
Fairly Down
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of IsoRay available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong SellUnder Valued
Financial Strength
IsoRay financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to IsoRay success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
IsoRay Inc (ISR) is traded on BATS Exchange in USA. It is located in 350 Hills Street and employs 43 people. IsoRay is listed under Medical Equipment category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with total capitalization of 24.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate IsoRay's market, we take the total number of it shares issued and multiply it by the IsoRay's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. IsoRay Inc runs under Healthcare sector within Medical Instruments & Supplies industry. The entity has 67.34 M outstanding shares of which 1.98 M shares are currently shorted by investors with about 6.85 days to cover shorted positions. ISORAY INC has about 6.39 M in cash with (5.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check IsoRay Probability Of Bankruptcy

Ownership Allocation (%)

IsoRay Stock Price Odds Analysis

Odds Down 0.7053HorizonTargetOdds Up 0.7053
79.44%30 days
Based on normal probability distribution, the odds of IsoRay to move above current price in 30 days from now is about 20.48 (This IsoRay Inc probability density function shows the probability of IsoRay Stock to fall within a particular range of prices over 30 days) .

IsoRay Income Statement Over Time

IsoRay Inc Income Statement is one of the three primary financial statements used for reporting IsoRay's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of IsoRay Inc revenue and expense. IsoRay Income Statement primarily focuses on the company's revenues and expenses during a particular period. IsoRay Cost of Revenue is relatively stable at the moment as compared to the last year. IsoRay reported last year Cost of Revenue of 3.84 Million. As of 06/05/2020, Interest Expense is likely to grow to 923.68, while Earning Before Interest and Taxes EBIT is likely to drop (5 M). View More Fundamentals
Consolidated Income    Interest Expense    Net Income    

IsoRay Stock Against Markets

Did you try this?

Run Portfolio Volatility Now


Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

IsoRay Upcoming and Recent Events

IsoRay Company Earnings Announcements Dates

Upcoming Quarterly Report22nd of September 2020
Next Earnings Report10th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End22nd of September 2020
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

IsoRay Corporate Filings

IsoRay SEC Reporting

Financial Statements and Exhibits. Other Events
Submission of Matters to a Vote of Security Holders
Other Events
Entry into a Material Definitive Agreement

IsoRay Corporate Directors

Alan Hoffmann Independent Director
Thomas LaVoy Independent Director
Philip Vitale Independent Director
Please see Risk vs Return Analysis. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page